MSA enters joint agreement with Mayo Clinic for blood and marrow transplant software.
With the rapid evolution of solid organ, blood and marrow, and cell transplantation, the need for a premium integrated application and database is paramount, MSA said in a press release. This is particularly the case when tracking and impacting outcomes for patients that receive both solid and non-solid transplantations. Clinical characteristics including demographics, disorders, source of organ or tissue immunosuppressive drug regimens to defend against GVHD and graft rejection are some of the focus areas of this joint development effort. Equally relevant will be the ability of the application to work across clinical disciplines and with outside parties, including relevant information transfer between cell therapy and interfacing with the UNOS and CIBMTR registries.
MSA said its EDIT software was designed as a tool specifically for transplant departments and clinics. EDIT is a full-featured, clinical, data-management solution for the unique requirements of a transplant center. EDIT tracks patients through post-transplant follow-up by seamlessly interfacing with internal and external data sources and clinical registries to create a comprehensive view focused on transplantation. The company said the comprehensive review is critical for patient care and required for research activities.
MSA also has offices in New York; Atlanta; High Point, NC; Las Vegas; Cardiff, UK; Shanghai, China and Kuala Lumpur, Malaysia. Go to: www.msa.com
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Business Briefs|
|Date:||Apr 1, 2013|
|Previous Article:||Pain killers could prove helpful in stem-cell transplants.|
|Next Article:||CryoLife gets FDA clearance for next generation HeRO Device.|